Ioversol
 | |
| Clinical data | |
|---|---|
| Trade names | Optiray |
| AHFS/Drugs.com | Multum Consumer Information |
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | Low |
| Metabolism | None |
| Elimination half-life | 90 min |
| Excretion | Kidneys |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.118.911 |
| Chemical and physical data | |
| Formula | C18H24I3N3O9 |
| Molar mass | 807.115 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Ioversol (INN; trade name Optiray) is an organoiodine compound that is used as a contrast medium. It features both a high iodine content, as well as several hydrophilic groups. It is used in clinical diagnostics including arthrography, angiocardiography and urography.[2][3]
References
[edit]- ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
- ^ "Optiray (ioversol) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 9 January 2021.
- ^ Chen Y, Huang X, Huang S, Matchett M (17 February 2011). "13. Fast-in-process method for the determination ioversol and related polar compounds by hydrophilic interactive chromatography". In Wang PG, He W (eds.). Hydrophilic Interaction Liquid Chromatography (HILIC) and Advanced Applications. CRC Press. p. 295-30. ISBN 978-1-4398-0753-8.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |